Literature DB >> 6410799

Positron emission tomographic studies of aging and Alzheimer disease.

M J de Leon, S H Ferris, A E George, D R Christman, J S Fowler, C Gentes, B Reisberg, B Gee, M Emmerich, Y Yonekura, J Brodie, I I Kricheff, A P Wolf.   

Abstract

In this study the positron emission tomographic (PET)-18F-2-deoxy-2-fluoro-D-glucose (FDG) technique was used to study both normal aging and senile dementia. The results derived from 15 young normal subjects (mean age, 26 +/- 5 years) and 22 elderly normal subjects (mean age, 66 +/- 7 years) failed to indicate significant metabolic changes associated with age. A group of 24 patients with senile dementia (mean age, 73 +/- 7 years) showed consistent diminutions in regional glucose use relative to the elderly normals. Across all brain regions the diminutions were 17%-24%. There were also significant correlations between the measures of glucose use and the measures of cognitive functioning. Discriminant function classification analysis results indicate that better than 80% classification accuracy can be achieved for individual PET measures. These data suggest a possible future diagnostic use of PET in senile dementia.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6410799      PMCID: PMC8334899     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  43 in total

1.  Feasibility and acceptance of simultaneous amyloid PET/MRI.

Authors:  Lisa Schütz; Donald Lobsien; Dominik Fritzsch; Solveig Tiepolt; Peter Werner; Matthias L Schroeter; Jörg Berrouschot; Dorothee Saur; Swen Hesse; Thies Jochimsen; Michael Rullmann; Bernhard Sattler; Marianne Patt; Hermann-Josef Gertz; Arno Villringer; Joseph Claßen; Karl-Titus Hoffmann; Osama Sabri; Henryk Barthel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-07-19       Impact factor: 9.236

2.  Effects of a dietary ketone ester on hippocampal glycolytic and tricarboxylic acid cycle intermediates and amino acids in a 3xTgAD mouse model of Alzheimer's disease.

Authors:  Robert J Pawlosky; Martin F Kemper; Yoshihero Kashiwaya; Michael Todd King; Mark P Mattson; Richard L Veech
Journal:  J Neurochem       Date:  2017-03-15       Impact factor: 5.372

3.  OPTIMIZING DIAGNOSIS AND MANANGEMENT IN MILD-TO-MODERATE ALZHEIMER'S DISEASE.

Authors:  James E Galvin
Journal:  Neurodegener Dis Manag       Date:  2012-06

Review 4.  Probing the biology of Alzheimer's disease in mice.

Authors:  Karen H Ashe; Kathleen R Zahs
Journal:  Neuron       Date:  2010-06-10       Impact factor: 17.173

Review 5.  Central and Peripheral Metabolic Defects Contribute to the Pathogenesis of Alzheimer's Disease: Targeting Mitochondria for Diagnosis and Prevention.

Authors:  Yunhua Peng; Peipei Gao; Le Shi; Lei Chen; Jiankang Liu; Jiangang Long
Journal:  Antioxid Redox Signal       Date:  2020-03-16       Impact factor: 8.401

6.  Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial.

Authors:  Samuel T Henderson; Janet L Vogel; Linda J Barr; Fiona Garvin; Julie J Jones; Lauren C Costantini
Journal:  Nutr Metab (Lond)       Date:  2009-08-10       Impact factor: 4.169

Review 7.  Ketone bodies as a therapeutic for Alzheimer's disease.

Authors:  Samuel T Henderson
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

Review 8.  Reassessment of Pioglitazone for Alzheimer's Disease.

Authors:  Ann M Saunders; Daniel K Burns; William Kirby Gottschalk
Journal:  Front Neurosci       Date:  2021-06-16       Impact factor: 4.677

Review 9.  Hypometabolism as a therapeutic target in Alzheimer's disease.

Authors:  Lauren C Costantini; Linda J Barr; Janet L Vogel; Samuel T Henderson
Journal:  BMC Neurosci       Date:  2008-12-03       Impact factor: 3.288

10.  The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer's Disease.

Authors:  S L Cole; R Vassar
Journal:  Curr Genomics       Date:  2007-12       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.